ReviewDigital health
Artificial intelligence in digital mental health technology: Considerations for regulation.
Review in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) is being introduced into all aspects of life with notable adoption seen in health care and systems and growing utility in the domain of digital mental health technology (DMHT). The Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Care Excellence in the UK are together exploring the regulation and evaluation of DMHT through a Wellcome-funded project. As part of this initiative, a symposium was held to bring together experts from across the AI and DMHT sector representing a breadth of disciplines, to share insights and inform the project. This review presents a reflection of the key opportunities and challenges of AI in DMHT with a focus on medical device regulation, distilling the main themes from the symposium. To facilitate responsible and agile regulation enabling access to high quality, safe, and effective medical products, regulators will need to continually adapt and develop, with new processes, guidance, initiatives and forums to fully engage in this innovative, exponentially developing field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.